Remove Bioinformatics Remove Clinical Development Remove Pharmaceuticals
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

By integrating diverse data sources and leveraging AI , the industry hopes to overcome the challenges of complex drug development and accelerate the delivery of effective treatments to patients. About the authors Remco Jan Geukes Foppen , PhD, is an AI and life sciences expert specialising in the pharmaceutical sector.

Drugs 65
article thumbnail

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. Financial terms of the new agreement are not disclosed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In Silico Modeling Unveils a New Era in Rare Disease Drug Development

The Premier Consulting Blog

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.

article thumbnail

United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis

The Pharma Data

We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

FDA 40
article thumbnail

Early evidence and emerging trends: How AI is shaping drug discovery and clinical development

Drug Target Review

Recently Recursion Pharmaceuticals unbiased, machine learning-powered genomics screen rapidly identified and advanced REC-1245. One way is to take a multimodal approach, using AI-driven image analysis, patient pre-selection via genotyping, and other tools to increase an already low probability of clinical success.

article thumbnail

Using clinical genomics and AI in drug development to elevate success

Drug Target Review

Drug development: addressing complexity and success rates Drug development is a complex and expensive process, requiring multidisciplinary expertise and high-risk financial investments. The major hurdles that pharmaceutical companies face are long lead times, high costs and a low probability of success (PoS).

article thumbnail

Bristol Myers Squibb Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

The Pharma Data

Presentation Topic: Clinical Trials. Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program. Presentation Topic: Biomarkers and Bioinformatics. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in DAYBREAK: an open-label extension study of ozanimod phase 1?3